胃肠道间质瘤中E-cadherin和MMP-9的表达及预后的多因素分析
|
摘要
目的:探讨胃肠道间质瘤(GIST)中E-cadherin和MMP-9表达的意义,以及包括E-cadherin和MMP-9在内的多种因素对GIST预后的影响。
方法:回顾分析2002年4月至2006年6月,湘雅医院78例GIST手术病人的临床和病理资料,并进行随访。参考Flecher等关于GIST的恶性潜能分级方法,应用免疫组化S-P法检测各组中E-cadherin和MMP-9的表达情况,分析临床特征、病理分级、E-cadherin和MMP-9的表达等多种因素对GIST术后2年复发转移率和5年生存率的影响。
结果:全组病人E-cadherin的阳性表达率为65.4%(51/78),MMP-9的阳性表达率为55.1%(43/78)。E-cadherin和MMP-9的表达在不同的性别年龄组无显著差异(P＞0.05),在高危组与其他组的比较中有显著差异(P＜0.05),列联系数C=0.908。全组病例2年复发转移率和5年生存率分别为31.8%、72.3%。单因素分析不同性别年龄组的2年复发转移率和5年生存率无显著差异(P＞0.05),肿瘤的原发部位、直径大小、核分裂相、E-cadherin和MMP-9的表达对肿瘤的预后影响显著(P＜0.05)。多因素分析显示,不同E-cadherin的表达对GIST的预后影响有显著性(P＜0.05)。
结论:E-cadherin及MMP-9在胃肠道间质瘤中均有表达,可能与GIST的生物学行为密切相关,在这个过程中,它们之间的作用成负相关。肿瘤的原发部位、大小、核分裂相、E-cadherin及MMP-9的表达情况与肿瘤的预后密切相关,E-cadherin的表达情况是独立预后因素。E-cadherin可望作为预测术后转移复发的指标,同时纳入肿瘤大小,核分裂相的Flecher恶性潜能分级方法结合E-cadherin和MMP-9的表达情况可能是评估GIST预后的更加准确合理的方法。
Objective:To investigate the relationship between the expression of E-cadherin,matrix metalloproteinases 9,and the prognosis of gastrointestinal stromal tumor(GIST).
Methods:The clinical and pathological data of 78 patients with GISTs admitted between April 2002 and June 2006 in Xiangya Hospital were analyzed.To refer to Flecher's classification in GISTs, immunohistochemical technique was used to investigate the expression of E-cadherin and MMP-9.To investigate the impacts of clinical feature,pathologic classification,expression of E-cadherin and MMP-9 on the 2-year recurrence and metastasis rate and 5-year survival rate in patients with GISTs.
Results:The positive rate of E-cadherin were 65.4%(51/78)and the positive rate of MMP-9 were 55.1%(43/78)The expression of E-cadherin and MMP-9 had no significant difference in gender,age (P＞0.05),but had significant difference in localization of tumor and the histological grade(P＜0.05).There was negative correlation between the expression of E-cadherin and MMP-9(C=0.908).The 2-year recurrence and metastasis rate and 5-year survival rate were 31.8%,72.3% respectively.No significiant differences in gender and age were existed. Primary organ,Tumor size,mitotic rate and expression of E-cadherin, MMP-9 were analysized respectively.The differences were significiant (P＜0.05).There were significiant differences in expression of E-cad in multiple factors analysis.
Conclusion:The expression of E-cadherin and MMP-9 are closely related to the biological behavior of GIST,which may be used as an objective parameter for distinguishing malignant from benign GIST. Primary organ,tumor size,mitotic rate and expression of E-cadherin,MMP-9 are important prognostic factors in GIST,and the expression of E-eadherin is independent prognostic factor.E-cadherin may be an indicator to forecast the recurrence and metastasis rate of GIST. To combine Fleeher's classification and the expression of E-cadherin, MMP-9 may be a more ratinal,scientific method in GIST's prognostic analysis.
方法:回顾分析2002年4月至2006年6月,湘雅医院78例GIST手术病人的临床和病理资料,并进行随访。参考Flecher等关于GIST的恶性潜能分级方法,应用免疫组化S-P法检测各组中E-cadherin和MMP-9的表达情况,分析临床特征、病理分级、E-cadherin和MMP-9的表达等多种因素对GIST术后2年复发转移率和5年生存率的影响。
结果:全组病人E-cadherin的阳性表达率为65.4%(51/78),MMP-9的阳性表达率为55.1%(43/78)。E-cadherin和MMP-9的表达在不同的性别年龄组无显著差异(P＞0.05),在高危组与其他组的比较中有显著差异(P＜0.05),列联系数C=0.908。全组病例2年复发转移率和5年生存率分别为31.8%、72.3%。单因素分析不同性别年龄组的2年复发转移率和5年生存率无显著差异(P＞0.05),肿瘤的原发部位、直径大小、核分裂相、E-cadherin和MMP-9的表达对肿瘤的预后影响显著(P＜0.05)。多因素分析显示,不同E-cadherin的表达对GIST的预后影响有显著性(P＜0.05)。
结论:E-cadherin及MMP-9在胃肠道间质瘤中均有表达,可能与GIST的生物学行为密切相关,在这个过程中,它们之间的作用成负相关。肿瘤的原发部位、大小、核分裂相、E-cadherin及MMP-9的表达情况与肿瘤的预后密切相关,E-cadherin的表达情况是独立预后因素。E-cadherin可望作为预测术后转移复发的指标,同时纳入肿瘤大小,核分裂相的Flecher恶性潜能分级方法结合E-cadherin和MMP-9的表达情况可能是评估GIST预后的更加准确合理的方法。
Objective:To investigate the relationship between the expression of E-cadherin,matrix metalloproteinases 9,and the prognosis of gastrointestinal stromal tumor(GIST).
Methods:The clinical and pathological data of 78 patients with GISTs admitted between April 2002 and June 2006 in Xiangya Hospital were analyzed.To refer to Flecher's classification in GISTs, immunohistochemical technique was used to investigate the expression of E-cadherin and MMP-9.To investigate the impacts of clinical feature,pathologic classification,expression of E-cadherin and MMP-9 on the 2-year recurrence and metastasis rate and 5-year survival rate in patients with GISTs.
Results:The positive rate of E-cadherin were 65.4%(51/78)and the positive rate of MMP-9 were 55.1%(43/78)The expression of E-cadherin and MMP-9 had no significant difference in gender,age (P＞0.05),but had significant difference in localization of tumor and the histological grade(P＜0.05).There was negative correlation between the expression of E-cadherin and MMP-9(C=0.908).The 2-year recurrence and metastasis rate and 5-year survival rate were 31.8%,72.3% respectively.No significiant differences in gender and age were existed. Primary organ,Tumor size,mitotic rate and expression of E-cadherin, MMP-9 were analysized respectively.The differences were significiant (P＜0.05).There were significiant differences in expression of E-cad in multiple factors analysis.
Conclusion:The expression of E-cadherin and MMP-9 are closely related to the biological behavior of GIST,which may be used as an objective parameter for distinguishing malignant from benign GIST. Primary organ,tumor size,mitotic rate and expression of E-cadherin,MMP-9 are important prognostic factors in GIST,and the expression of E-eadherin is independent prognostic factor.E-cadherin may be an indicator to forecast the recurrence and metastasis rate of GIST. To combine Fleeher's classification and the expression of E-cadherin, MMP-9 may be a more ratinal,scientific method in GIST's prognostic analysis.
引文
[1]Plaat BE,Hollema H,Molenaar WM,et al.Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors:differences in clinical outcome and expression of multidrug resistance proteins[J].J Clin Oncol,2000,18:3211-3220.
[2]Ng EH,Pollock RE,Munsell MF,et al.Prognostic factors influencing survival in gastrointestinal leiomyosarcomas:implications for surgical management and staging[J].Ann Surg,1992,215:68-77.
[3]Byan C,Ronald P,DeMatteo MD,et al.Gastrointestinal stormal tumors and leiomyosarcoma of the abdomen and retroperitoneum:A Clin Compar[J].Ann Serg Oncol,2001,8:290-299.
[4]马大烈,白辰光.胃肠道间质瘤的病理诊断和预后[J].世界华人消化杂志.2006,14(24):2367-2371。
[5]Fletcher CD,Berman JJ,Corless C.Diagnosis of gastrointestinalstromal tumors:a consensus approach[J].Hum Pathol,2002,33(5):459 - 465.
[6]Nagafuchi A,Shirayoshi Y,Okazald K,Yasuda K,Takeichi M.Transformation of cell adhesion properties by exogenously introduced E-cadherin cDNA[J].Nature,1987,329:341-343.
[7]Hirohashi S.Inactivation of the E-cadherin mediated cell adhesion system in human cancers[J].Am J Pathol,1998,153:333-339.
[8]Shiozald H,Tahara H,Oka H,Miyata M,et al.Experession of immunoreactive E-cadherin adhesion molecules in human cancers[J].Am J Pathol,1991,139:17-23.
[9]Elzagheid A,Algara A,Bendardaf R.Lamlum H,Ristamaki R.Collan Y,Syrjanen K,Pyrhonen S.E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome[J].Word J Gastroenterol,2006,12:4304-4309.
[10]House MG.Guo M,Efron DT,Lillemoe KD,Cameron JL,Syphard JE,Hooker CM et al.tumor suppressor gene hypermethylation as a predictor of gastic stomal tumor behavior[J].J Gastroitest Surg,2003,7:1004-1014.
[11]Aznavoorian S,Murphy AN,Stetler-Stevenson WG.et al.Molecular aspects of tumor cell invasion and metastasis[J].Cancer,1993,71:1368-1383.
[12]李杰茹,齐风英.基质金属蛋白酶抑制剂与肿瘤侵袭转[J].国外医学:肿瘤学分册,2004,31(6):409.
[13]朱宝和,詹文华,刘弋,等.PTEN与基质金属蛋白酶在胃癌组织中的表达及意义[J].中国现代普通外科进展,2006,9(1):33-36.
[14]朱民,姜金波,寿楠海.大肠癌组织中MMP-2、MMP-7的基因表达[J].中国现代普通外科进展,2004,7(6):358-359.
[15]La Rocoa G.Pacci-Minafra I,Marrazzo A,et al.Zymogrophic detectionand clinical correlations of MMP- 2 and MMP- 9 in breastcancer sera[J].Br J Cancer,2004,90(7):1414.
[16]Park DW,Ryui- IS,Choi DS,et al.Localization of matrix metal oproteinase on endometrial cancer cell invasion invitrol[J].Gynecol On col,2001,82(3):442-449.
[17]Llorens A,Rodrigo I,Lopez-Barcons L,et al.Down-regulation of E-cadherin in mouse skin carcinoma cells a migratory and invasive phenotype linked to matrix metalloproteinase-9 gelatinaseexpression[J].Lab Invest,1998,78(9):1131.
[18]Shimizu M,Raitoh Y,Ltoh H,et al.Immunohistochemical staining of Ha-ras oncogene product in normal,benign,and malignant human pancreatic tissues[J].Hum pathol,1990,21(6):607-612.
[19]Miettinen M,Furlong M,Sarlomo-R ikala M,et al.Gastrointestinal stromal tumors,intramuralleiomyomas,and leiomyo sarcomas in the rectum andanus:a clinicopatho logic,immunohistochemical,and molecular genetic study of 144cases[J].Am J Surg Pathol,2001,25(9):1121- 1133.
[20]杜春燕,师英强等.胃肠道间质瘤103例预后分析[J].中国实用外科杂志,2007,27(4):297-299.
[21]De Matteo RP,Lewis JJ,Leung D,etal.Two hundred gastrointestinal stormal tumors:recurrence patterns and prognostic factors for survival[J].Ann Surg,2000,231:51-58.
[22]ChOU FF,ENG HL,CHEN SM,et al.smooth muscle tumor of the gastrointestinal tract:analysis of prognostic factors[J].Surgery,1996,119:171-177.
[23]Amin MB,Ma CK,Linden MD,et al.Prognostic value of proliferating cell nuclear antigen index in gastric stromal tumors.Correlation with mitotic count and clinical outcome[J].Am J ClinPathol,1993,100:428-432.
[24]Trupiano JK,Stewart RE,Misick C,et al.Gastric stromal tumors:a clinicopathologie study of 77 cases with correlation of features with nonaggressive and aggressive clinical behaviors[J].Am J Surg Pathol,2002,26:705-714.
[25]Berman J,O'leary TJ.Gastrointestinal stromal tunmor workshop[J].Hum Pathol,2001,32(6):578 - 582.
[26]Brinker BT,Krown SE,Lee JY,Cesarman E,Chadburn A,Kaplan LD,Henry DH,Von Roenn JH.Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma:a multicenter trial of the AIDS Malignancy Consortium[J].Cancer,2008,112(5):1083-1088
[27]Kim HJ,Lee JY,Kim SH,Seo YJ,Lee JH,Park JK,Kim MH,Cinn YW,Cho KH,Yoon TY.Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans:comparison with factor ⅩⅢa and CD34[J].Br J Dermatol,2007,157(2):319-324.
[1]Mazur MT,Clark HB.Gastric stromal tumor:reappraisal of histogenesis[J].Am J Surg Pathol,1983,7:507.
[2]Miettinen M,Lasota J.Gastrointestinal stromal tumors definition,clinical,histololgical,immunohistochemical,and molecular genetic features and differential diagnosis[J].Virchows Arch,2001,438:1.
[3]Fletcher CD,Berman JJ,Corless C.Diagnosis of gastrointestinalstromal tumors: a consensus approach[J].Hum Pathol,2002,33(5):459 - 465.
[4]Dematteo RP,Lewis JJ,Leung D,et al.Two hundred gastrointestinal stromaltumors:recurrence patterns and prognostic factors for survival[J].Ann Surg,2000,231(1):51-58.
[5]Vannucchi MG.Receptors in intestinal cells of cajal:identification and possible physiological roles[J].Microsd Resea Tech,1999,47:3252-3351.
[6]候英勇,朱雄增.胃肠道平滑肌瘤的组织发生及命名[J].中华病理学杂志,2000,29(6):4532-4571
[7]Tsujimura K,Hashimoto K,KITayma H,et al.Activating mutation in the catalytic domain of c-KIT elicits hematopoietictransformation by receptor self-association not at the ligandinduced dimerization site[J].Blood,1999,93(4):2592-3091
[8]Lasota J,Jasinski M,Sarlomo-Rikala M,et al.Mutations in exen 11 of c-KIT occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas[J].Am J Pathol,1999,154(1):532-601
[9]Johanna A,Helena S,Jeanne MM,et al.The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal(pacemaker cell)tumours[J].Am J Pathol,2002,160(1):152-221.
[10]Hirota S,Isozald K,Moriyama Y,et al.Gain- of- function mutations of c-KIT in human gastrointestinal stromal tumors[J].Science,1998,279(5350):5772-5801
[11]Heinrich MC,Corless CL,Duensing A,et al.PDGFRA activating mutations in gastrointestinal stromal tumors[J].Science,2003,299(5607):707-710.
[12]Hirota S,Ohashi A,Nishida T,et al.Gain-of-function mutations of platelet-derived growth factor receptor alpgha gene in gastrointestinal stromal tumors[j].Gastroenterology,2003,125(3):660-667
[13]Miettinen,Markku,Sobin,et al.Gastrointestinal stromal tumors of the stomach:A clinicopathologic,immunohestochemical,and molecular genetic study of 1765cases with long-term follow-up[j].Am J Surg Pathol,2005,29(1):52-68.
[14]Fakasawa T,Chong JM,Sakarai S,et al.Allelic loss of 14q and 22q,NF2mutation and genetic instability qccur independently of c-kit mutation in gastrointestinal stromal tumor.Jpn J Cancer Res,2000,91:124121249.
[15]Lasota J,Wozniak A,Kopczynski J,et al.Loss of heterozygosity on chromosome 22q in gastrointestinal stromal tumors(GISTs):a study on 50cases.Lab Invest,2005,85:237-247.
[16]Debiec-gycher M,Lasota J,Sarlomo-Rikala M,et al.Chromosomal aberrations inmalignant gastrointestinal stromal tumors:correlation with c-kit gene mutation.Cancer Genet Cytogenet,2001,128:24-30.
[17]Choi YR,Kim H,Kang HJ,et al.Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation.Cancer Res,2003,63:2188-2193.
[18]Sheehan KM,Mrcp MS,Cummins RJ,et al.Cyclooxygenase22 expression in stromal tumors of the gastrointestinal tract.Human Pathol,2003,34:1242-1246.
[19]Nakatani H,Kobayashi M,Jin T,et al.STI571(Glivec)inhibits the interaction between c-KIT and heat shock protein 90 of the gastrointestinal stromal tumor cell line,GIST-T1.Cancer Sci,2005,96:116-119.
[20]Morimoto K,Nishimori I,Takeuchi T,et al.Overexpression of carbonic ananhydr ase-related protein Ⅺ promotes proliferation and invasion of gastrointestinal stromal tumors.Virchows Arch,2005,447:66-73.
[21]Fletcher CD,Berman JJ,Corless C,et al.Diagnosis of gastrointestinal stromal tumors:a consensus approach[J].Intl J SurgPathol,2002,10:81- 89.
[22]Ghanem N,Altehoefer C,Furtwangler A,et al.Computed tomography in gastrointestinal stromal tumors[J].Eur gadiol,2003,13:1669 - 1678.
[23]Okai T,Minamoto T,Ohtsubo K,et al.Endosonographic evaluation of c-kit positive gastrointestinal stromal tumors[J].AbdomImaging,2003,28:301 - 307.
[24]Davila RE,Faigel DO.GI.A nice summary of the current status of endoscopic diagnosis and therapy for GISTs[J].Gastrointest Endosc,2003,58:80-88.
[25]Gu M,Ghafari S,Nguyen PT,et al.Cytologic diagnosis of gastrointestinal stromal tumors of the stomach by endoscopic ultrasound guided fine needle aspiration biopsy:cytomorphologic andimmunohistochemical study of 12 cases [J].Diagn Cytopathol,2001,25:343 - 350.
[26]Ando N,Goto H,Niwa Y,et al.The diagnosis of GI stromal tumors with EUS2guided fine needle aspiration and immunohistochemical analysis[J]Gastrointest Endosc,2002,55:37-43.
[27]An Den Abbeele AD,Badawi RD.Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors(Gists)[J].Eur J Cancer,2002,38(suppl5):S60-65.
[28]Stroobants S,Goeminne J,Seegers M,et al.18 FDG2positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mcsylate[J].Eur J Cancer,2003,39:2012 - 2020.
[29]Sakurai S,Oguni S,Hironaka M,et al.Mutations in c-kit gene exon9 and 13 in gastrointestinal stromaltumors among Japancse[J].Jpn J Cancer Res,2001,92(5):494-498.
[30]Miettinen,Markku,Sobin,et al.Gastrointestinal strgmal tumors of the stomach:A clinicopathologic,immunohestochemical,and molecular genetic study of 1765cases with long-term follow-up[J].Am J Surg Pathol,2005,29(1):52-68.
[31]Demetri GD,van Osterom AT,Blackstein M,et al.Phase 3,multicenter,randomized,double2blind,placebo2controlled trial of SU1248 in patients(pts)following failure of imatinib for metastatic GIST[J].Proc ASCO,2005,23:308.
[32]Evans TRJ,Morgan JA,van dan Abbeele AD,et al.Phase 1 Dose-escalation study of the SRC and multi2kinase inhibitor BMS-354825 in patients(pts)with GIST and other solid tumors[J].Proc ASCO,2005 ＄23:200.
[33]Tamborini E,Bonadiman L,Greco L,et al.A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.Gastroenterology.2004;127:294-299.
[34]Chen LL,Sabripour M,Andtbacka RH,et al.Imatinib resistance in gastrointestinal stromal tumors.Curr Oncol Pep.2005;7:293-299.
[35]Antonescu CR.Besmer P,Guo T,et al.Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.Clin Cancer ges.2005;11:4182-4190.
[36]Debiec-gychter M,Cools J,Dumez H,et al.Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib resistant mutants.Gastroenterology.2005;128:270-279.
[37]Roberts PJ,Eisenberg B.Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease[J].Eur J Cancer,2002,38(suppl 5):37s - 38s.
[38]Ematteo RP,Maki RG.Antonescu C,et al.Targeted molecular therapy for cancer:the application of STI571 to gastrointestinal stromal tumor[J].Curr Probl Surg,2003,40:144 - 193.
[39]刘晓红,马大烈,吴丽莉等。原癌基因c-KIT在胃肠道肿瘤中的表达及其临床意义[J].中华外科杂志2002,40:277-279.
[40]Miettinen M,El-Rifai W,H L Sohin L,Lasota J.Evaluation of maligalignancy and prognosis of gastrointestinal stromal tumors:a review.Hum Pathal 2002,33:478-483.
[41]Kim KM,Kang DW,Moon WS,Park JB,Park CR.Sohn JH et al.Gastrointesinal stromal tumors in Koreans:it's incidence and the clinical,pathologic and immunohistochemical findings.J Korean Med Sci 2005,20:977-984.
[42]Hasegawa T,Matsuno Y,Shimoda T,Hirohashi S.Gastrointestinal stromal tumor:consistent CD117 immunostaining for diagnosis,and prognostic classification based on tumor size and MIB-1 grade.Hum Pathol 2002,33:669-676.
[43]马大烈,刘晓红,白辰光,谢强,冯菲.c-KIT基因突变对胃肠道间质瘤预后的影响.中华外科杂志[J].2004,42:140-144.
[44]Tornoczky T,Kovor E,Pajor L.Frequent occurrence of low grade cases among metastatic gastrointestinal stromal tumors.J Clin Pathol 2003,56:363-367.
[45]Corless CL,Fletcher JA,Heinrich MC.Biology of gastrointestinal stromal tumors.J Clin Oncol 2004,22:3813-3825.
[46]Laota J,Dansonka-Mieszkowska A,Sobin HL,Miettinen M.A great majority of GISTs with PDGFRA mutations represent gastic tumors of low or no malignant potential.Lab Invest 2004,84:874-883.
[47]贺慧颖,方伟岗,钟镐镐,李燕等。165例胃肠道间质瘤中c-KIT和PDGFRA 基因突变的检测和临床意义[J].中华病理学杂志2006,35:262-266.
[48]House MG.Guo M,Efron DT,Lillemoe KD,Cameron JL,Syphard JE,Hooker CM et al.tumor suppressor gene hypermethylation as a predictor of gastic stomal tumor behavior.J Gastroitest Surg 2003,7:1004-1014.
[49]El-Rifai W,Sarlomo-rikala M,Andersson LC,Knuutila S,Miettinen M.DNA sequence copy number changes in gastrointestinal stromal tumors:tumor progression and prognostic significance.Cancer Res 2000,60:3899-3903.
[50]Sabah M,Cummins R,Leader M,Kay E.Expression of human telomerase reverse transcriptase in gastrointestinal stromal tumors occurs preferentially in malignant neoplasma.Hum Pathol 2004,35:1231-1235.
[51]gossi CR.Mocellin S,Mencarelli R.et al.Gastrointestinal stromal tumors:from asurgical to a molecular approach.Int J Cancer 2003,107:171-176.
[52]杜春燕,师英强,傅红,赵广法,周烨,蔡国响.胃肠道间质瘤103例预后分析.中国实用外科杂志[J].2007,4(27):297-299.
[53]Byan C,Ronald P,Dematteo MD,et al.Gastrointestinal stromal tumors an leiomyosarcoma of the abdomen and retroperitoneum:A Clin Compar Ann Surg Oncol,2001,8:290-299.
[2]Ng EH,Pollock RE,Munsell MF,et al.Prognostic factors influencing survival in gastrointestinal leiomyosarcomas:implications for surgical management and staging[J].Ann Surg,1992,215:68-77.
[3]Byan C,Ronald P,DeMatteo MD,et al.Gastrointestinal stormal tumors and leiomyosarcoma of the abdomen and retroperitoneum:A Clin Compar[J].Ann Serg Oncol,2001,8:290-299.
[4]马大烈,白辰光.胃肠道间质瘤的病理诊断和预后[J].世界华人消化杂志.2006,14(24):2367-2371。
[5]Fletcher CD,Berman JJ,Corless C.Diagnosis of gastrointestinalstromal tumors:a consensus approach[J].Hum Pathol,2002,33(5):459 - 465.
[6]Nagafuchi A,Shirayoshi Y,Okazald K,Yasuda K,Takeichi M.Transformation of cell adhesion properties by exogenously introduced E-cadherin cDNA[J].Nature,1987,329:341-343.
[7]Hirohashi S.Inactivation of the E-cadherin mediated cell adhesion system in human cancers[J].Am J Pathol,1998,153:333-339.
[8]Shiozald H,Tahara H,Oka H,Miyata M,et al.Experession of immunoreactive E-cadherin adhesion molecules in human cancers[J].Am J Pathol,1991,139:17-23.
[9]Elzagheid A,Algara A,Bendardaf R.Lamlum H,Ristamaki R.Collan Y,Syrjanen K,Pyrhonen S.E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome[J].Word J Gastroenterol,2006,12:4304-4309.
[10]House MG.Guo M,Efron DT,Lillemoe KD,Cameron JL,Syphard JE,Hooker CM et al.tumor suppressor gene hypermethylation as a predictor of gastic stomal tumor behavior[J].J Gastroitest Surg,2003,7:1004-1014.
[11]Aznavoorian S,Murphy AN,Stetler-Stevenson WG.et al.Molecular aspects of tumor cell invasion and metastasis[J].Cancer,1993,71:1368-1383.
[12]李杰茹,齐风英.基质金属蛋白酶抑制剂与肿瘤侵袭转[J].国外医学:肿瘤学分册,2004,31(6):409.
[13]朱宝和,詹文华,刘弋,等.PTEN与基质金属蛋白酶在胃癌组织中的表达及意义[J].中国现代普通外科进展,2006,9(1):33-36.
[14]朱民,姜金波,寿楠海.大肠癌组织中MMP-2、MMP-7的基因表达[J].中国现代普通外科进展,2004,7(6):358-359.
[15]La Rocoa G.Pacci-Minafra I,Marrazzo A,et al.Zymogrophic detectionand clinical correlations of MMP- 2 and MMP- 9 in breastcancer sera[J].Br J Cancer,2004,90(7):1414.
[16]Park DW,Ryui- IS,Choi DS,et al.Localization of matrix metal oproteinase on endometrial cancer cell invasion invitrol[J].Gynecol On col,2001,82(3):442-449.
[17]Llorens A,Rodrigo I,Lopez-Barcons L,et al.Down-regulation of E-cadherin in mouse skin carcinoma cells a migratory and invasive phenotype linked to matrix metalloproteinase-9 gelatinaseexpression[J].Lab Invest,1998,78(9):1131.
[18]Shimizu M,Raitoh Y,Ltoh H,et al.Immunohistochemical staining of Ha-ras oncogene product in normal,benign,and malignant human pancreatic tissues[J].Hum pathol,1990,21(6):607-612.
[19]Miettinen M,Furlong M,Sarlomo-R ikala M,et al.Gastrointestinal stromal tumors,intramuralleiomyomas,and leiomyo sarcomas in the rectum andanus:a clinicopatho logic,immunohistochemical,and molecular genetic study of 144cases[J].Am J Surg Pathol,2001,25(9):1121- 1133.
[20]杜春燕,师英强等.胃肠道间质瘤103例预后分析[J].中国实用外科杂志,2007,27(4):297-299.
[21]De Matteo RP,Lewis JJ,Leung D,etal.Two hundred gastrointestinal stormal tumors:recurrence patterns and prognostic factors for survival[J].Ann Surg,2000,231:51-58.
[22]ChOU FF,ENG HL,CHEN SM,et al.smooth muscle tumor of the gastrointestinal tract:analysis of prognostic factors[J].Surgery,1996,119:171-177.
[23]Amin MB,Ma CK,Linden MD,et al.Prognostic value of proliferating cell nuclear antigen index in gastric stromal tumors.Correlation with mitotic count and clinical outcome[J].Am J ClinPathol,1993,100:428-432.
[24]Trupiano JK,Stewart RE,Misick C,et al.Gastric stromal tumors:a clinicopathologie study of 77 cases with correlation of features with nonaggressive and aggressive clinical behaviors[J].Am J Surg Pathol,2002,26:705-714.
[25]Berman J,O'leary TJ.Gastrointestinal stromal tunmor workshop[J].Hum Pathol,2001,32(6):578 - 582.
[26]Brinker BT,Krown SE,Lee JY,Cesarman E,Chadburn A,Kaplan LD,Henry DH,Von Roenn JH.Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma:a multicenter trial of the AIDS Malignancy Consortium[J].Cancer,2008,112(5):1083-1088
[27]Kim HJ,Lee JY,Kim SH,Seo YJ,Lee JH,Park JK,Kim MH,Cinn YW,Cho KH,Yoon TY.Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans:comparison with factor ⅩⅢa and CD34[J].Br J Dermatol,2007,157(2):319-324.
[1]Mazur MT,Clark HB.Gastric stromal tumor:reappraisal of histogenesis[J].Am J Surg Pathol,1983,7:507.
[2]Miettinen M,Lasota J.Gastrointestinal stromal tumors definition,clinical,histololgical,immunohistochemical,and molecular genetic features and differential diagnosis[J].Virchows Arch,2001,438:1.
[3]Fletcher CD,Berman JJ,Corless C.Diagnosis of gastrointestinalstromal tumors: a consensus approach[J].Hum Pathol,2002,33(5):459 - 465.
[4]Dematteo RP,Lewis JJ,Leung D,et al.Two hundred gastrointestinal stromaltumors:recurrence patterns and prognostic factors for survival[J].Ann Surg,2000,231(1):51-58.
[5]Vannucchi MG.Receptors in intestinal cells of cajal:identification and possible physiological roles[J].Microsd Resea Tech,1999,47:3252-3351.
[6]候英勇,朱雄增.胃肠道平滑肌瘤的组织发生及命名[J].中华病理学杂志,2000,29(6):4532-4571
[7]Tsujimura K,Hashimoto K,KITayma H,et al.Activating mutation in the catalytic domain of c-KIT elicits hematopoietictransformation by receptor self-association not at the ligandinduced dimerization site[J].Blood,1999,93(4):2592-3091
[8]Lasota J,Jasinski M,Sarlomo-Rikala M,et al.Mutations in exen 11 of c-KIT occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas[J].Am J Pathol,1999,154(1):532-601
[9]Johanna A,Helena S,Jeanne MM,et al.The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal(pacemaker cell)tumours[J].Am J Pathol,2002,160(1):152-221.
[10]Hirota S,Isozald K,Moriyama Y,et al.Gain- of- function mutations of c-KIT in human gastrointestinal stromal tumors[J].Science,1998,279(5350):5772-5801
[11]Heinrich MC,Corless CL,Duensing A,et al.PDGFRA activating mutations in gastrointestinal stromal tumors[J].Science,2003,299(5607):707-710.
[12]Hirota S,Ohashi A,Nishida T,et al.Gain-of-function mutations of platelet-derived growth factor receptor alpgha gene in gastrointestinal stromal tumors[j].Gastroenterology,2003,125(3):660-667
[13]Miettinen,Markku,Sobin,et al.Gastrointestinal stromal tumors of the stomach:A clinicopathologic,immunohestochemical,and molecular genetic study of 1765cases with long-term follow-up[j].Am J Surg Pathol,2005,29(1):52-68.
[14]Fakasawa T,Chong JM,Sakarai S,et al.Allelic loss of 14q and 22q,NF2mutation and genetic instability qccur independently of c-kit mutation in gastrointestinal stromal tumor.Jpn J Cancer Res,2000,91:124121249.
[15]Lasota J,Wozniak A,Kopczynski J,et al.Loss of heterozygosity on chromosome 22q in gastrointestinal stromal tumors(GISTs):a study on 50cases.Lab Invest,2005,85:237-247.
[16]Debiec-gycher M,Lasota J,Sarlomo-Rikala M,et al.Chromosomal aberrations inmalignant gastrointestinal stromal tumors:correlation with c-kit gene mutation.Cancer Genet Cytogenet,2001,128:24-30.
[17]Choi YR,Kim H,Kang HJ,et al.Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation.Cancer Res,2003,63:2188-2193.
[18]Sheehan KM,Mrcp MS,Cummins RJ,et al.Cyclooxygenase22 expression in stromal tumors of the gastrointestinal tract.Human Pathol,2003,34:1242-1246.
[19]Nakatani H,Kobayashi M,Jin T,et al.STI571(Glivec)inhibits the interaction between c-KIT and heat shock protein 90 of the gastrointestinal stromal tumor cell line,GIST-T1.Cancer Sci,2005,96:116-119.
[20]Morimoto K,Nishimori I,Takeuchi T,et al.Overexpression of carbonic ananhydr ase-related protein Ⅺ promotes proliferation and invasion of gastrointestinal stromal tumors.Virchows Arch,2005,447:66-73.
[21]Fletcher CD,Berman JJ,Corless C,et al.Diagnosis of gastrointestinal stromal tumors:a consensus approach[J].Intl J SurgPathol,2002,10:81- 89.
[22]Ghanem N,Altehoefer C,Furtwangler A,et al.Computed tomography in gastrointestinal stromal tumors[J].Eur gadiol,2003,13:1669 - 1678.
[23]Okai T,Minamoto T,Ohtsubo K,et al.Endosonographic evaluation of c-kit positive gastrointestinal stromal tumors[J].AbdomImaging,2003,28:301 - 307.
[24]Davila RE,Faigel DO.GI.A nice summary of the current status of endoscopic diagnosis and therapy for GISTs[J].Gastrointest Endosc,2003,58:80-88.
[25]Gu M,Ghafari S,Nguyen PT,et al.Cytologic diagnosis of gastrointestinal stromal tumors of the stomach by endoscopic ultrasound guided fine needle aspiration biopsy:cytomorphologic andimmunohistochemical study of 12 cases [J].Diagn Cytopathol,2001,25:343 - 350.
[26]Ando N,Goto H,Niwa Y,et al.The diagnosis of GI stromal tumors with EUS2guided fine needle aspiration and immunohistochemical analysis[J]Gastrointest Endosc,2002,55:37-43.
[27]An Den Abbeele AD,Badawi RD.Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors(Gists)[J].Eur J Cancer,2002,38(suppl5):S60-65.
[28]Stroobants S,Goeminne J,Seegers M,et al.18 FDG2positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mcsylate[J].Eur J Cancer,2003,39:2012 - 2020.
[29]Sakurai S,Oguni S,Hironaka M,et al.Mutations in c-kit gene exon9 and 13 in gastrointestinal stromaltumors among Japancse[J].Jpn J Cancer Res,2001,92(5):494-498.
[30]Miettinen,Markku,Sobin,et al.Gastrointestinal strgmal tumors of the stomach:A clinicopathologic,immunohestochemical,and molecular genetic study of 1765cases with long-term follow-up[J].Am J Surg Pathol,2005,29(1):52-68.
[31]Demetri GD,van Osterom AT,Blackstein M,et al.Phase 3,multicenter,randomized,double2blind,placebo2controlled trial of SU1248 in patients(pts)following failure of imatinib for metastatic GIST[J].Proc ASCO,2005,23:308.
[32]Evans TRJ,Morgan JA,van dan Abbeele AD,et al.Phase 1 Dose-escalation study of the SRC and multi2kinase inhibitor BMS-354825 in patients(pts)with GIST and other solid tumors[J].Proc ASCO,2005 ＄23:200.
[33]Tamborini E,Bonadiman L,Greco L,et al.A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.Gastroenterology.2004;127:294-299.
[34]Chen LL,Sabripour M,Andtbacka RH,et al.Imatinib resistance in gastrointestinal stromal tumors.Curr Oncol Pep.2005;7:293-299.
[35]Antonescu CR.Besmer P,Guo T,et al.Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.Clin Cancer ges.2005;11:4182-4190.
[36]Debiec-gychter M,Cools J,Dumez H,et al.Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib resistant mutants.Gastroenterology.2005;128:270-279.
[37]Roberts PJ,Eisenberg B.Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease[J].Eur J Cancer,2002,38(suppl 5):37s - 38s.
[38]Ematteo RP,Maki RG.Antonescu C,et al.Targeted molecular therapy for cancer:the application of STI571 to gastrointestinal stromal tumor[J].Curr Probl Surg,2003,40:144 - 193.
[39]刘晓红,马大烈,吴丽莉等。原癌基因c-KIT在胃肠道肿瘤中的表达及其临床意义[J].中华外科杂志2002,40:277-279.
[40]Miettinen M,El-Rifai W,H L Sohin L,Lasota J.Evaluation of maligalignancy and prognosis of gastrointestinal stromal tumors:a review.Hum Pathal 2002,33:478-483.
[41]Kim KM,Kang DW,Moon WS,Park JB,Park CR.Sohn JH et al.Gastrointesinal stromal tumors in Koreans:it's incidence and the clinical,pathologic and immunohistochemical findings.J Korean Med Sci 2005,20:977-984.
[42]Hasegawa T,Matsuno Y,Shimoda T,Hirohashi S.Gastrointestinal stromal tumor:consistent CD117 immunostaining for diagnosis,and prognostic classification based on tumor size and MIB-1 grade.Hum Pathol 2002,33:669-676.
[43]马大烈,刘晓红,白辰光,谢强,冯菲.c-KIT基因突变对胃肠道间质瘤预后的影响.中华外科杂志[J].2004,42:140-144.
[44]Tornoczky T,Kovor E,Pajor L.Frequent occurrence of low grade cases among metastatic gastrointestinal stromal tumors.J Clin Pathol 2003,56:363-367.
[45]Corless CL,Fletcher JA,Heinrich MC.Biology of gastrointestinal stromal tumors.J Clin Oncol 2004,22:3813-3825.
[46]Laota J,Dansonka-Mieszkowska A,Sobin HL,Miettinen M.A great majority of GISTs with PDGFRA mutations represent gastic tumors of low or no malignant potential.Lab Invest 2004,84:874-883.
[47]贺慧颖,方伟岗,钟镐镐,李燕等。165例胃肠道间质瘤中c-KIT和PDGFRA 基因突变的检测和临床意义[J].中华病理学杂志2006,35:262-266.
[48]House MG.Guo M,Efron DT,Lillemoe KD,Cameron JL,Syphard JE,Hooker CM et al.tumor suppressor gene hypermethylation as a predictor of gastic stomal tumor behavior.J Gastroitest Surg 2003,7:1004-1014.
[49]El-Rifai W,Sarlomo-rikala M,Andersson LC,Knuutila S,Miettinen M.DNA sequence copy number changes in gastrointestinal stromal tumors:tumor progression and prognostic significance.Cancer Res 2000,60:3899-3903.
[50]Sabah M,Cummins R,Leader M,Kay E.Expression of human telomerase reverse transcriptase in gastrointestinal stromal tumors occurs preferentially in malignant neoplasma.Hum Pathol 2004,35:1231-1235.
[51]gossi CR.Mocellin S,Mencarelli R.et al.Gastrointestinal stromal tumors:from asurgical to a molecular approach.Int J Cancer 2003,107:171-176.
[52]杜春燕,师英强,傅红,赵广法,周烨,蔡国响.胃肠道间质瘤103例预后分析.中国实用外科杂志[J].2007,4(27):297-299.
[53]Byan C,Ronald P,Dematteo MD,et al.Gastrointestinal stromal tumors an leiomyosarcoma of the abdomen and retroperitoneum:A Clin Compar Ann Surg Oncol,2001,8:290-299.